alpine immune sciences stock forecast
© The company traded as high as $14.60 and last traded at $13.62. Historical Ratings. There are currently 28,151 Alpine Immune Sciences shares held short by investors – that's known as Alpine Immune Sciences's "short interest". 16 Nov. 4:05PM. Past Monthly Recommendations. Although still a year away from treating afflicted patients, Alpine’s novel approach could result in game-changing therapies down the road. A number of analysts […] HC Wainwright is very positive to ALPN and gave it a "Buy" rating on December 21, 2020. Last 30 Days. Alpine Immune Sciences Inc., formerly known as Nivalis Therapeutics, is based in Seattle, Washington. Alpine (ALPN) Looks Good: Stock Adds 7.8% in Session Zacks. For Alpine Immune profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Alpine Immune to generate income relative to revenue, assets, operating costs, and current equity. Actual. Companies: ALPN . A high-level overview of Alpine Immune Sciences, Inc. (ALPN) stock. stock was originally listed at a price of $59.68 in Jun 17, 2015. Earnings vs Savings Rate: ALPN is forecast to remain unprofitable over the next 3 years. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The stock has a consensus analyst rating of "Buy." Please note that any opinions, estimates or forecasts regarding Alpine Immune Sciences, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Alpine Immune Sciences, Inc. or its management. 15 Nov. 7:03AM. Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovering of protein-based immunotherapies therapies targeting the immune synapse to treat cancer, autoimmune, and inflammatory disorders. Alpine Immune Sciences Inc (ALPN) Stock Earning Per Share (EPS) Forecast / Estimate $-0.313 The average consensus EPS for ALPN is $-0.313 with a high estimate of $-0.137 and Low of $-0.490 for the period 2021-06-30 and based on 6 Institutional Analysts. Shorting Alpine Immune Sciences shares. Read More . (RTTNews) - Shares of Alpine Immune Sciences, Inc. (ALPN) more-than-doubled on Thursday morning. Alpine Immune Sciences to Participate in Fireside Chat at the Evercore ISI 3rd Annual HealthCONx Virtual Conference Business Wire. Alpine will host a … Alpine Immune Sciences Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. However, solely looking at the historical price movement is usually misleading. If you had invested in Alpine Immune Sciences stock at $59.68, your return over the last 5 years would have been -79.31%, for an annualized return of -27.03%. ALPN stock forecast Our latest prediction for Alpine Immune Sciences Inc's stock price was made on the Dec. 28, 2020 when the stock price was at 15.44$.. View the latest ratings for ALPN. This Buy consensus rating has held steady for over two years. How is Alpine Immune Sciences forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?-10.5%. Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN) rose 5.2% on Tuesday . AC Investment Inc. delivers machine learning based share price forecast. Get the latest stock price for Alpine Immune Sciences Inc. (ALPN:US), plus the latest news, recent trades, charting, insider activity, and analyst ratings. The price target was set to $21.00. Alpine Immune Sciences to Participate in Fireside Chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference Business Wire. Alpine Immune Sciences Inc has risen higher in 2 of those 5 years over the subsequent 52 week period, corresponding to a historical probability of 40 % Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. Alpine Immune Sciences, Inc. is followed by the analysts listed above. Alpine Immune Sciences, Inc. Common Stock, also called Alpine Immune Sciences, is a development-stage pharmaceutical company. Introducing Alpine Immune Sciences (NASDAQ:ALPN), The Stock That Dropped 43% In The Last Year. ALPINE IMMUNE SCIENCES INC stock price forecast for further price development up to 0.12% (time horizon: 1 day) and price target of 12.97 USD. It offers Immunotherapy, Immune Synapse, vIgD Platform Technology, and … Alpine Immune Sciences last announced its quarterly earnings results on November 17th, 2020. Approximately 351,923 shares traded hands during mid-day trading, an increase of 142% from the average daily volume of 145,189 shares. Read More The firm engages in the discovering of protein-based immunotherapies therapies targeting the immune synapse to treat cancer, autoimmune, and inflammatory disorders. SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will release fourth quarter and full year 2020 financial results on Thursday, March 18, 2021 after the close of market. Investors can use this forecasting interface to forecast Alpine Immune historical stock prices and determine the direction of Alpine Immune Sciences's future trends based on various well-known forecasting models. Alpine Immune Sciences Inc Stock Forecast. Is Alpine Immune Sciences Inc (ALPN) Stock a Good Value? ALPINE IMMUNE SCIENCES, INC. : Trading strategies, financial analysis, commentaries and investment guidance for ALPINE IMMUNE SCIENCES, INC. Stock | Nasdaq: ALPN | Nasdaq It engages in the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders and other diseases. ALPN's price/sales ratio is 64.24; that's higher than the P/S ratio of 95.16% of US stocks. Find the latest Alpine Immune Sciences, Inc. (ALPN) stock quote, history, news and other vital information to help you with your stock trading and investing. Most Recent Rating. Tuesday, March 9, 2021, 2:53 PM | InvestorsObserver Analysts . In the short term (2weeks), ALPN's stock price should underperform the market by -4.15%.During that period the price should oscillate between … Tuesday, March 9, 2021, 2:53 PM | InvestorsObserver Analysts . Analyst Future Growth Forecasts . The stock had previously closed at $12.95. A "buy" rating indicates that analysts believe ALPN will outperform the market and that investors should add to their positions of Alpine Immune Sciences. This figure is 4.6% up from 26,922 last month. Alpine Immune Sciences. These fundamental indicators attest to how well Alpine Immune Sciences utilizes its assets to generate profit and value for its shareholders. There are a few different ways that this level of interest in shorting Alpine Immune Sciences shares can be evaluated. Trading Signals for Alpine Immune Sciences Inc with Buy, Sell, Hold recommendations, technical analysis, and trading strategy. SEATTLE --(BUSINESS WIRE)--Feb. 22, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will participate at … Earnings and Revenue Growth Forecasts. Alpine Immune Sciences currently has 6 buy ratings from Wall Street analysts. The firm earned $1.91 million during the quarter, compared to the consensus estimate of $4.80 million. Forecasted annual earnings growth. Alpine Immune Sciences Inc Stock Forecast NASDAQ:ALPN Price Target and Analyst Ratings. It offers Immunotherapy, Immune Synapse, vIgD Platform Technology, and TIP Program. Business Wire-5.06%. Get alerts on ALPN - Alpine Immune Sciences, Inc. Learn more about Earnings Per Share (EPS) Last Quarter. Short-term (time horizon: 2 weeks) ALPINE IMMUNE SCIENCES INC share price prediction for 2021-03-19 with daily closed price projections Companies: SEM . Where Does SINTX Technologies Inc (SINT) Stock Fall in the Medical … Alpine Immune Sciences Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 11.41% of US listed stocks. Buy The current consensus among 5 investment analysts is to buy stock in Alpine Immune Sciences. Estimate. Should You Hold Select Medical Holdings Corporation (SEM) Stock Tuesday? The average price target is $19.00, with a high forecast of $22.00 and a low forecast of $17.00. Alpine Immune Stock Forecast is based on your current time horizon. We value your privacy. Simply Wall St. 10:27AM : Investors Who Bought Alpine Immune Sciences (NASDAQ:ALPN) Shares A Year Ago Are Now Down 43% . Simply Wall St. Jun-03-19 07:35AM : Alpine Immune Sciences Appoints Biopharma Veteran Wayne Gombotz as Chief Technology Officer. Read More . The average price target represents a 132.27% upside from the last price of $8.18. Over the next 52 weeks, Alpine Immune Sciences Inc has on average historically risen by 26.8 % based on the past 5 years of stock performance. ALPINE IMMUNE SCIENCES, INC. earnings per share revisions and analysts forecast | Nasdaq: ALPN | Nasdaq ALPN Stock Summary. Analyst … 24 Nov. 4:05PM. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by $0.05. See Alpine Immune Sciences, Inc. (ALPN) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.